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Dear Sir/Madam 
We read with interest Morrison et al. ‘Early detection and intervention evaluation for people 
at risk of psychosis: a multisite randomised controlled trial’ as well as the subsequent 
coverage in the Guardian http://www.guardian.co.uk/society/2012/apr/06/drugs-psychosis-
schizophre... 
The authors’ concluded that cognitive therapy did not significantly reduce transition to 
psychosis or symptom related distress. However, the most surprising finding of the study was 
the low transition rate (8%), which meant that the study was not sufficiently powered to detect 
a true difference between the interventions. The authors suggest several reasons for this: the 
exclusion of participants at risk of imminent transition; the sampling and recruitment strategy 
may have led to including participants who, due to their pathways into care and degree of 
help-seeking, may not have been ‘risk enriched’ [1-3]; those most at risk may not be willing 
to enter trials; the relatively short follow-up period; and that the ‘control’ condition 
(monitoring of mental state, with warm, empathic supportive listening) may itself have 
reduced transition rates. Whatever the reasons, the transition rate was much lower than that 
reported in the existing literature. A recent meta-analysis of 27 studies found that in a 
combined sample of about 2500 subjects, the transition rate was 18% at 6 months after onset 
of symptoms, 22% at 1 year, 29% at 2 years, and 32% at 3 years [4]. In agreement with the 
meta-analytic cohort findings, substantially higher 12 months transition rates (12.5% to 
37.5%) were observed in the control conditions of earlier randomised controlled intervention 
trials in this population [5-10]. 
It would be interesting to know how many of the cohort remitted from the at-risk mental state 
during their time in the study, and whether this was influenced by the two interventions [11]. 
The clinical significance of the results is difficult to interpret because the ordinal CAARMS 
intensity scales appear to have been weighted by the corresponding frequency ratings to create 
a 'severity scale' which was statistically analysed as though it were a continuous variable. The 
authors then commented that a 4 point reduction in this severity scale represented clinically 
significant change. However, spread across the four subscales examined this might actually 
reflect a modest clinical change.  
The authors reported that of n=634 participants assessed for eligibility, n=346 were excluded 
and n=288 were randomised. Of those excluded, 156 either were taking antipsychotic 
medication or were found to be psychotic (24.6%) and n=110 were sub threshold for 
psychosis (17.35%). It is worth bearing in mind that many of those on anti-psychotics will not 
have had a psychotic disorder, but have been at-risk subjects with a relatively high risk of 
transition [12]. Hence, excluding this group may have contributed to the low transition rate. In 
the study by Morrison et al, 45.4% of those assessed met inclusion criteria. However, in an 
earlier publication from the same group that described the study design [13], the authors 
indicated that n=867 participants had been referred to the study, suggesting that n=233 were 
not assessed. This was reported as being due to a loss of contact or subjects lacking interest. 
However, this loss of potential participants is another potential source of bias, as these 
individuals may be those who are the most distressed or disadvantaged, and hence at greatest 
risk of psychosis. Without knowing more about the sampling procedures employed by the 
study, such as how the team tried to engage with those with whom they had lost contact, and 
demographic data comparing this subgroup to those included in the study, it is hard to know 
whether this may have also contributed to the low transition rate. 
The authors suggest that the low transition rate that they identified raises questions about the 
validity of the At Risk Mental State. However, given how atypical the rate is relative to that in 
the literature, this may be premature. The concept of the At Risk Mental State has stimulated 
a body of new research that has significantly advanced our knowledge of the mechanisms 
underlying psychosis [14-22], and has led to the development of clinical services that permit 
the earlier detection and management of mental health problems [23, 24]. Research at this 
stage is a particularly powerful way of investigating the mechanisms underlying psychosis, as 
the same individual can be studied before and after the onset of illness, without the 
confounding effects of previous treatment or long-lasting disease-related effects [25]. 
Nevertheless, the data from this and other studies [26-29] suggest that the existing inclusion 
criteria, which are relatively recent and mainly based on positive psychotic symptoms [11, 30-
35], could certainly be improved. In particular, it would be useful to include items relating to 
affective and negative psychotic symptoms, and self-perceived [36] and cognitive changes 
[37] or through the introduction of second step risk stratification [38, 39]. 
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